NY Hospitals Pocket Federal Drug Savings
- Dr. Lisa Grabert’s March 19 analysis says New York hospitals in the 340B drug program are steering discount profits into investments, not patient relief. - The sharpest number is $191 million — the average stocks-and-bonds holdings at New York 340B hospitals, versus $95.4 million at non-340B peers. - The fight now is over oversight, as Albany weighs a bill forcing hospitals to disclose how much of 340B savings reaches patients.
Hospitals are supposed to use federal 340B drug discounts to stretch scarce resources for low-income care. In New York, the latest fight is over whether many of them are doing something else with that money instead. A March 19 analysis by health policy researcher Lisa Grabert argues that 340B hospitals in the state are piling more of those savings into investments and expensive contract labor while giving patients little direct benefit. That matters because Albany is also debating whether to protect and expand parts of the program without first forcing much more disclosure. (betterhospitalsnow.org) ### What is 340B, exactly? 340B is a federal drug-pricing program for safety-net providers. Drugmakers have to sell outpatient medicines to eligible hospitals and clinics at steep discounts — often roughly 20% to 50% below list price. Hospitals can then bill insurers at regular rates and keep t(betterhospitalsnow.org)to pass the discount directly to the patient standing at the counter. (ncsl.org) ### What did the New York analysis say? Grabert’s analysis says New York 340B hospitals had average revenue of $932 million, more than double the $423 million reported by non-340B hospitals. It also says the 340B hospitals held average investments of $191 million in stocks and bonds, versus $95.4 million at non-340B facilities — a 42% gap. (ncsl.org)revenue engine. (betterhospitalsnow.org) ### Are patients seeing the savings? That is the core complaint — and the answer from critics is mostly no. The analysis says charity-care levels at New York 340B hospitals were not meaningfully higher, as a share of operations, than at non-340B hospitals despite the extra revenue. It also high(betterhospitalsnow.org) but it shows why the program keeps drawing heat. (betterhospitalsnow.org) ### Why do investments matter so much? Because investments are a clean signal of what management chooses to do with excess cash. If a hospital says it needs 340B savings to support vulnerable patients, critics expect to see more uncompensated care, lower patient drug costs, or expanded services(betterhospitalsnow.org)healthcare — but not in the way the public assumes. (betterhospitalsnow.org) ### What about staffing? The analysis also points to labor choices. It says New York 340B hospitals paid contract workers nearly twice what they paid full-time employees on average. One hospital CEO, the paper says, earned more than $15 million — 163 times average nurse pay. Those details sharpen the political argument that the savings are not obviously flowing to bedside care either. (betterhospitalsnow.org) ### Why is Albany involved now? New York lawmakers are weighing a transparency bill, A6987/S8380, that would require covered entities to report how they use 340B discounts and what percentage of patients actually benefit. The bill was introduced in March 2025 and was referred again to the Assem(betterhospitalsnow.org)politically defended. (nysenate.gov) ### Is this just a New York problem? No. Nationally, spending by covered entities on 340B drug purchases rose from $66 billion in 2023 to $81 billion in 2024. States across the country are now fighting over contract pharmacies, manufacturer restrictions, and transparency rules. New York just makes the tension especially visible because the hospitals are large, the numbers are large, and the reporting debate is active right now. (ncsl.org) ### So what’s the bottom line? The real issue is not whether hospitals are allowed to keep a spread. They are. The issue is whether a program sold as help for vulnerable patients can stay politically intact if hospitals cannot show where the money went. In New York, that question is no longer abstract — it is sitting in a live legislative fight. (nysenate.gov)
